DOCSLIB.ORG

Title of Presentation Arial 50Pt Bold

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Title of Presentation Arial 50Pt Bold Biologics Risks and Benefits of Treating Inflammation Leonard H Calabrese Professor of Medicine RJ Fasenmyer Chair of Clinical Immunology Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures • LH Calabrese, C Calabrese • COI managed by the Cleveland Clinic Innovation Management & Conflict of Interest Program http://cc-clcoirpt51.cc.ad.cchs.net/COIProd. - Consultant Pfizer Jansen Sanofi GSK Roche - Speaker Genentech, Abbive, Jansen, BMS, Crescendo Flow of Immunity with Age The Effect of HIV Infection and Its Treatment on Inflammation and Immunosenescence Deeks SG et al, Annu Rev Med. 2011. 62:141-55 Immune-mediated Inflammatory Diseases Initiation Susceptibility Triggers Accelerants Innate Immune responses Adaptive Inflammation (TNF, IL-1, IL-6, IL-17, IL-23, IL-18, IL-15, Others) Damage / Destruction / Symptoms (RA, SLE, PsA, IBD, AS, MS) DM, CHF, Alzheimer's, Transplant, Sepsis, Allergy, Vasculitis, ASO, HIV Evolution of BIOLOGICS for IMIDS (USA-Approved partial list) Infliximab Adalimumab Golimumab Gold D-Penicillamine Etanercept Certolizumab 1940s 1950s 1960s 1970s 1980s 1990s 2000sAnakinra* Leflunomide Rituximab Hydroxychloroquine Methotrexate Abatacept Corticosteroids Auranofin Azathioprine Tocilizumab Ustikinumab Belimumab Natalizumab Canakinumab Rilonacept Tofacitinib Molecules in development RA (ACR 2014) Compound Phase 1 Phase 2a Phase 2b Phase 3 Approved Kinase inhibitors Tofacitinib (JAK 3/1/2) Fostamatinib (syk) Baricitinib (JAK 1/2) VX-509 (JAK 3/1) GLPG0634 (JAK 1) ASP015K (JAK 1/3) IL-6 inhibitors Sarilumab (anti-IL-6R mAb) Sirukumab Olokizumab ALX-0061 (anti-IL-6R nanobody) IL-17 inhibitors Ixekizumab Secukinumab Brodalumab (anti-IL-17R mAb) SUSPENDED Molecules in development RA (ACR 2014) Compound Phase 1 Phase 2a Phase 2b Phase 3 Targeted B cell therapies NNC0109-0012 (anti-IL-20 mAb) Ocaratuzumab (anti-CD20 mAb) Tabalumab (anti-BAFF/Blys mAb) SUSPENDED Atacicept SBI-087 Biosimilar GP2013 (rituximab) Other molecules PPARγ agonist IFNα kinoid vaccination NNC141-0100 (anti-NKG2a mAb) NNC0114-0005 (anti-IL-21 mAb) Ozoralizumab (ATN-103) Vagal Nerve Stimulation Dekavil (F8-IL-10) GnRH antagonist IV Staph protein A Tregalizumab (anti-CD-4 mAb) Mavrilimumab (anti-GM-CSFRα) CCX354-L2 (chemokine inhibitor) ARG098 (intra-articular anti-FAS IgM mAb) Candidate molecules/pathways • TNF • IL-6 • IL-1 targeting • Anti T cell therapies • Others IL17, GM-CSF, IL12/23 Addition of Warning Information in Anti-TNFα Labels Over Time Data collected during clinical trials and postmarketing surveillance Legionella Listeria Leukemia Pediatric malignancy Invasive fungal infections HBV HSTCL Hepatotoxicity Exposure CHF Malignancies Tuberculosis Neurologic Events Hematologic Events Sepsis Infections Hypersensitivity 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 FDA web site. Available at: http://www.fda.gov. ENBREL® (etanercept) Prescribing Information, Immunex Corporation. REMICADE® (infliximab) Prescribing Information, Centocor Ortho Biotech, Inc. HUMIRA® (adalimumab) Prescribing Information, Abbott Laboratories. SIMPONI™ (golimumab) Prescribing information, Centocor Ortho Biotech, Inc. CIMZIA® (certolizumab pegol) Prescribing Information, UCB Inc. Determining Toxicity of Drugs in Clinical Trials – Tools and Limitations • Events - Infections – routine, opportunistic - Non infectious complications • Autoimmune – cytopenias, SLE, MS • Malignancy, Cardiovascular disease • Infusion reactions, hypersensitivity • Frequency - Common 1/100 - Rare 1/1000 - Extremely rare 1/10,000 Problems with Analyzing Toxicity from RCT • Short duration • High drop out rate in placebo group • Not powered for AEs - Rule of three (3000 subjects for a 95% CI of 1/1000) Registry and / or Observational Data Problems Interpreting Data • Confounding by indication (“channeling”) • Variation in selection of comparator drug cohort • Variations in duration of follow-up • Confounding by indication • Difficulty in controlling for bias • Assumptions of hazard function over time • Voluntary reporting in “post marketing” i.e. Med watch Molecular Structures of TNF-α InhibitorsHuman recombinant receptor/Fc fusion protein Humanized Fab’ fragment Human recombinant Chimeric antibodies monoclonal Receptor VL VH antibody CL CH1 Constant 2 CDR Fc Constant 3 PEG PEG Infliximab Adalimumab Golimumab Etanercept IgG1 IgG1 IgG1 IgG1 Certolizumab Mouse Human CDR=Complementarity-determining region PEG=Polyethylene glycol Structural differences not indicative of differences in efficacy or safety Adapted from Tracey D et al. Pharmacol Ther. 2008;117:244-279. Differences among approved agents • PK • Cellular toxicity (apoptosis, C mediated, reverse signaling ) - CRTZ - ETN • Immunoregulatory • Immunogenicity Differential toxicity profiles • Infections - Bacterial mycobacterial fungal - Viral – HBV VZV - opportunistic • Autoimmunity • Malignancy – NHL? • Congestive failure • Demyelinating diseases • OTHERS: liver, cytopenias The Use of anti-TNF in HIV+ patients w/rheumatic disease •Retrospective series Infection Rate in HIV Patients Who Received TNF-α Inhibitor Therapy for Concomitant Autoimmune Diseases BACKGROUND: Few HIV-infected patients have been treated with tumor necrosis factor (TNF) -α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety of TNF-α inhibitor therapy in HIV-infected individuals is limited and based on isolated case reports and small series. 26 cases with no untoward toxicity when clinically and virologically controlled American College of Rheumatology 2015 IL1 signaling • IL1 alpha and beta, IRAP, IL18, IL33 • IL1 beta – IL1type 1receptor • Produced by cells of hematopoetic and non-hematopoetic lineage in response to external and internal danger signals • Pleotropic activites similar to TNF but augments T cell proliferation and IL2 production IRAP - anakinra Dubois E et al. Br J Clin Pharmacol. 71:5, 639-641. IL1 and inflammation Canakinumab Anti-inflammatory Thrombosis Outcomes Study CANTOS Study NCT101327846 • Phase III DBPCT RTC • Primary endpoint: Time to 1st CV event 36 months • 152 centers- 17,200 patients • Intervention: quarterly infusions of canakinumab IL-6 is Produced by Multiple Cell Types and Is Associated with Numerous Biologic Activities1,2 Mesenchymal cells, Monocytes/ Endothelial cells fibroblasts/ macrophages synoviocytes T-cell activation T cell differentiation IL-6 Hepatocytes TH17 Acute-phase response Maturation of Hepcidin, CRP megakaryocytes ↓ CYP450 B-cells Osteoclast activation Bone resorption Thrombocytosis Auto-antibodies (RF) Hyper-γ-globulinemia Adapted from 1 Firestein GS. Nature. 2003; 423:356-361. 2 Smolen JS, et al. Nat Rev Drug Disc. 2003; 2:473-488. IMNL-SCT-019940 Targeting Inflammatory Pathways: IL-6 as an Example Ahmed, et al. Mol Cancer Ther. 2007;6:2386-2390 Currently (February 2013), tocilizumab is approved by the EMA and FDA for use in RA, and tofacitinib is approved by the FDA for use in RA Sirukumab IL-6 Target the Jansen ligand Sarilumab (Reg Olokizumab Sanofi) UCB (& Tocilizumab)\ Clazakizumab ALX0061 BMS IL-6R gp130 Cell Surface P JAK P STAT Tofacitinib STAT P STAT Baricitinib P GLPG0634 VX-509 STAT ⇌ P STAT Nucleus P Transcription Additional safety signals • Infections - bacterial • Cytopenias 1-2% no correlation with IE • Lipids – significance ? • Lower GI perforations in patients with previous history of diverticulitis • Liver – moderate increase in LFTs ; no SAE Effects of IL-6 blockade in Treated HIV Infection CD4 <350, VL - ND 50% enrolled I. To examine the effects of systemic IL-6 inhibition on the pathogenesis of immune failure and inflammation in treated HIV infection. II. To examine the effect of systemic IL-6 inhibition on indices of cardiovascular risk in treated HIV-1 infection. III. To examine the effects of systemic IL-6 inhibition on the inflammatory transcriptome and plasma metabolomes in treated HIV-1 infection. T cell directed therapies T cell directed therapies • Abatacept (CTLA4-Ig) approved RA in trials vasculitis, other IMIDS • Belatacept –approved anti-rejection therapy • Anti CTLA4 – ipilimumab approved various cancers • Anti-PD1 –Nivolumab Immune checkpoints regulate different components in the evolution of an immune response. WHY DO WE NEED THEM??? Original Article Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, M.D., Steven J. O'Day, M.D., David F. McDermott, M.D., et Nal Engl J Med Volume 363(8):711-723 August 19, 2010 Activity of Anti–Programmed Death 1 (PD-1) Antibody (Nivolumab) in Patients with Treatment-Refractory Melanoma, Non–Small-Cell Lung Cancer, or Renal- Cell Cancer. pembrolizumab Topalian SL et al. N Engl J Med 2012;366:2443-2454 exhaustion or senescence ? COULD THERE BE BENEFICIAL EFFECTS OF IMMUNOLOGIC EXHAUSTION? Expression of classical markers of immune development that occur with aging Multiple co-stimulatory and inhibitory interactions regulate T cell responses Realities of Biologic Therapies in Inflammation and aging Clinical Immunologists Conclusion • Therapeutic armamentarium for IMIDS is rich • Many/any of these agents can be re- purposed for anti- aging strategies • The no harm principle is of paramount importance and predictors for such calculations are often flawed Immune Phenotypes of Cancer and Protracted Infection. CANCER INFECTIONS Hotchkiss RS, Moldawer LL. N Engl J Med 2014;371:380- 383. IL-17 based drugs • Secukinimab Novartis ABA head to head TNF- IR - – ongoing in Ps PsA,SpA **** uveitis • Ixekizumab Lily anti-IL17A –
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Tabalumab for Systemic Lupus Erythematosus
    Horizon Scanning Centre May 2014 Tabalumab for systemic lupus erythematosus SUMMARY NIHR HSC ID: 5581 Tabalumab (LY-2127399) is intended to be used as second line therapy for the treatment of systemic lupus erythematosus (SLE). If licensed, it would offer an additional treatment option for patients who have active moderate to severe SLE despite treatment with glucocorticoids, anti-malarials, and/or immunosuppressants; a group who currently have few effective therapies This briefing is available. Tabalumab is a human anti-B-cell activating factor (BAFF or B based on lymphocyte stimulator [BLyS]) monoclonal antibody. It is administered information subcutaneously, in contrast to the only existing licensed BAFF antagonist, which is administered via IV infusion. available at the time of research and a The annual incidence of SLE in the UK is between 3 and 4 cases per limited literature 100,000 population, which equates to approximately 1,600 and 2,100 new search. It is not cases in England per year. The estimated prevalence of SLE is 25-28 per intended to be a 100,000 population, commensurate with around 15,000 people in England definitive statement with the disease. SLE is associated with considerable morbidity and on the safety, mortality, with 10-year survival rates ranging from 70% to 92%. Around 40– efficacy or 70% of SLE patients develop renal involvement which confers a worse effectiveness of the prognosis for survival; and approximately 10% of patients with lupus nephritis health technology develop end-stage renal failure requiring dialysis or transplantation. covered and should Neuropsychiatric involvement occurs in 27% of people with SLE, and SLE is not be used for also characterised by haematological features and cardiovascular commercial complications.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Biologic Armamentarium in Psoriasis
    Vol 9, Issue 1, 2016 ISSN - 0974-2441 Review Article BIOLOGIC ARMAMENTARIUM IN PSORIASIS GANESH PAI1*, NITHIN SASHIDHARAN2 1Medical Director, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. 2Consultant Clinical Pharmacologist, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. Email: [email protected] Received: 14 July 2015, Revised and Accepted: 24 August 2015 ABSTRACT Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional treatments, and biologic therapies potential. Keywords: Psoriasis, Biologic, Non-biologic treatment. INTRODUCTION migration, potentiation of Th1 type of response, angiogenesis, and epidermal hyperplasia [7]. Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition with prevalence ranging 1-3% in the TNF- is plays vital role in the pathogenesis of psoriasis. It acts by world [1].
    [Show full text]
  • Study Protocol
    PROTOCOL SYNOPSIS A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus International Coordinating Investigator Study site(s) and number of subjects planned Approximately 450 subjects are planned at approximately 173 sites. Study period Phase of development Estimated date of first subject enrolled Q2 2015 3 Estimated date of last subject completed Q2 2018 Study design This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab (150 mg or 300 mg) versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age. Approximately 450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to receive a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous (IV) infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. Randomisation will be stratified using the following factors: SLE Disease Activity Index 2000 (SLEDAI-2K) score at screening (<10 points versus ≥10 points); Week 0 (Day 1) OCS dose 2(125) Revised Clinical Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00005 Edition Number 5 Date 18 May 2016 (<10 mg/day versus ≥10 mg/day prednisone or equivalent); and results of a type 1 interferon (IFN) test (high versus low).
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • New Drug Therapies for Systemic Lupus
    icine- O ed pe M n l A a c n c r e e s t s n I Beenken, Intern Med 2018, 8:1 Internal Medicine: Open Access DOI: 10.4172/2165-8048.1000268 ISSN: 2165-8048 Review Article Open Access New Drug Therapies for Systemic Lupus Erythematosus: A Systematic Review Beenken AE* Institute for Medical Immunology at the Campus Charité Mitte of the Medical Faculty of the Charité - Universitätsmedizin Berlin, Germany *Corresponding author: Beenken AE, Institute for Medical Immunology, Berlin, Germany, Tel: 4915161419493; E-mail: [email protected] Received date: January 31, 2018; Accepted date: February 20, 2018; Published date: February 25, 2018 Copyright: © 2018 Beenken AE, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract From the literature research the belimumab studies were the only ones to meet the primary and some of the secondary endpoints. Introduction: Systemic Lupus Erythematosus (SLE) is a multiorganic autoimmune disease caused by an immune reaction against DNA. Despite continuous research progress, the mortality of SLE patients is still 2‐4 times higher than the healthy populations and the standard drugs’ adverse effects (especially corticosteroids) hamper the patients’ quality of life. That is why there is an urgent need for new therapies. This paper reviews all phase III clinical trials of new SLE medication that were published since 2011 and analyses the drugs for their respective effects. Methods: MEDLINE (PubMed), Livivo, The Cochrane Library and Embase were systematically searched for relevant publications.
    [Show full text]
  • Report, Please Call the Telephone Number Listed
    201R1e port M E D I C I N E S I N D E V E L O P M E N T F O R Arthritis P R E S E N T E D B Y A M E R I C A ’ S B I O P H A R M A C E U T I C A L R E S E A R C H C O M P A N I E S Biopharmaceutical Research Companies are Developing Nearly 200 Medicines for the Most Common Chronic Health Problem in the United States merica’s biopharmaceutical research companies are MEDICINES AND VACCINES IN DEVELOPMENT FOR ARTHRITIS* currently developing 198 medicines to help the Behcet’s Syndrome 3 more than 50 million Americans afflicted with at A Duchenne Muscular Dystrophy 6 least one of the 100 different musculoskeletal disorders, Fibromyalgia 9 including arthritis. All of the medicines are either in Gout 7 clinical trials or awaiting review by the U.S. Food and Lupus 19 Muscle Disorders 11 Drug Administration. Osteoarthritis 19 Osteoporosis 23 Arthritis is the most common cause of disability in the Pain 15 United States. Each year, it is responsible for 44 million Psoriatic Arthritis 7 outpatient doctor visits, nearly 1 million hospitalizations, Raynaud’s Disease 4 and nearly 10,000 deaths. And it costs the American Rheumatoid Arthritis 67 Scleroderma 6 economy nearly $128 billion annually in direct medical Spondylitis 7 costs and indirect costs, such as lost wages and Other 22 productivity. * Some medicines are listed in more than one category.
    [Show full text]
  • The Future of B-Cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 2, April, 2017 https://doi.org/10.4078/jrd.2017.24.2.65 Review Article The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus William Stohl Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA To review B-cell activating factor (BAFF)-antagonist therapy in systemic lupus erythematosus (SLE), literature was searched us- ing the search words and phrases, “BAFF”, “B lymphocyte stimulator (BLyS)”, “a proliferation-inducing ligand (APRIL)”, “B-cell maturation antigen (BCMA)”, “transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI)”, “BLyS receptor 3 (BR3)”, “belimumab”, “atacicept”, “blisibimod”, “tabalumab”, and “lupus clinical trial”. In addition, papers from the author’s personal library were searched. BAFF-antagonist therapy in SLE has a checkered past, with four late-stage clin- ical trials meeting their primary endpoints and four failing to do so. Additional late-stage clinical trials are enrolling subjects to address some of the remaining unresolved questions, and novel approaches are proposed to improve results. The BAFF-centric pathway is a proven therapeutic target in SLE. As the only pathway in the past 50+ years to have yielded an United States Food and Drug Administration-approved drug for SLE, it occupies a unique place in the armamentarium of the practicing rheumatologist. The challenges facing clinicians and investigators are how to better tweak the BAFF-centric pathway and im- prove on the successes realized. (J Rheum Dis 2017;24:65-73) Key Words.
    [Show full text]
  • MEDICAL JOURNAL Yongwen Jiang, Phd (USPS 464-820), a Monthly Publication, Is Deborah N
    RHODE ISLAND M EDICAL J OURNAL Body Worlds Vital visits Rhode Island, page 66 R SPECIAL SECTION ADVANCES IN AUTOIMMUNE DISEASES GUEST EDITOR: EDWARD V. LALLY, MD DECember 2016 VOLUME 99 • NUMBER 12 ISSN 2327-2228 Your records are secure. Until they’re not. Data theft can happen to anyone, anytime. A misplaced mobile device can compromise your personal or patient records. RIMS IBC can get you the cyber liability insurance you need to protect yourself and your patients. Call us. 401-272-1050 IN COOPERATION WITH RIMS IBC RIMS INSURANCE BROKERAGE CORPORATION 405 PROMENADE STREET, SUITE B, PROVIDENCE RI 02908-4811 MEDICAL PROFESSIONAL/ CYBER LIABILITY PROPERTY/ CASUALTY LIFE/HEALTH/ DISABILITY RHODE ISLAND M EDICAL J OURNAL 18 Newer Treatment Strategies for Autoimmune Diseases EDWARD V. LALLY, MD GUEST EDITOR E. Lally, MD 19 Targeted Immunomodulatory Therapy: An Overview ASHLEY L. LEFEBVRE, PharmD, CDOE LAURA MCAULIFFE, PharmD: PGY2 23 Systemic Lupus Erythematosus: A. Lefebvre, PharmD A Review of the Clinical Approach to Diagnosis and Update on Current Targeted Therapies JOANNE SZCZYGIEL CUNHA, MD KATARZYNA GILEK-SEIBERT, MD J. Cunha, MD 28 Pemphigus: Pathogenesis to Treatment K. Gilek-Siebert, MD CHRISTOPHER DIMARCO, MD 32 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): C. DiMarco, MD Clinical Features, Diagnosis, and Current Treatment Strategies JACQUES REYNOLDS, DO GEORGE SACHS, MD, PhD G. Sachs, MD, PhD KARA STavROS, MD 36 Autoimmune Cytopenias: Diagnosis & Management CHRISTIAN P. NIXON, MD, PhD JOSEPH D. SWEENEY, MD C. Nixon, MD, PhD RHODE ISLAND M EDICAL J OURNAL 8 COMMENTARY Medical Tourism JOSEPH H. FRIEDMAN, MD Dickensian Diagnostics: The Diseases of Christmas Past What ailed Scrooge and Tiny Tim? HERBERT RAKATANSKY, MD Reconnecting with my Purpose in the Kingdom of Bhutan ERIC COHEN, MD 17 RIMJ AROUND THE WORLD New York, New York 58 RIMS NEWS Are you reading RIMS Notes? Working for You Weight + Wellness Summit Why You Should Join RIMS 66 SPOTLIGHT Body Worlds Exhibit: Anatomy Up Close & Personal MARY KORR 78 HeritaGE Dec.
    [Show full text]
  • The Role of Tumor Necrosis Factor Alpha (TNF-)
    International Journal of Molecular Sciences Review The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics Dan-in Jang 1,†, A-Hyeon Lee 1,† , Hye-Yoon Shin 2, Hyo-Ryeong Song 1,3 , Jong-Hwi Park 1, Tae-Bong Kang 4 , Sang-Ryong Lee 5,* and Seung-Hoon Yang 1,* 1 Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea; [email protected] (D.-i.J.); [email protected] (A.-H.L.); [email protected] (H.-R.S.); [email protected] (J.-H.P.) 2 School of Life Science, Handong Global University, Pohang, Gyeongbuk 37554, Korea; [email protected] 3 Department of Pharmacy, College of Pharmacy, Yonsei University, Seoul 03722, Korea 4 Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea; [email protected] 5 Department of Biological Environmental Science, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea * Correspondence: [email protected] (S.-R.L.); [email protected] (S.-H.Y.) † These authors contributed equally to this work. Abstract: Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the Citation: Jang, D.-i.; Lee, A-H.; Shin, necrosis of tumors, but it has been recently identified to have additional important functions as a H.-Y.; Song, H.-R.; Park, J.-H.; Kang, pathological component of autoimmune diseases. TNF-α binds to two different receptors, which T.-B.; Lee, S.-R.; Yang, S.-H. The Role initiate signal transduction pathways.
    [Show full text]